Notice of allowance of Breast Cancer Patent in Japan
DiaGenic has received notice of allowance of the family 3 patent
application in Japan ( 2007-514130). The claims allowed cover the use of
some important gene sequences in blood sample for detection and
monitoring of breast cancer. The patent will be valid until 2025. Family
3 patents have earlier been granted in US and Europe.
"The new Japanese patent is an important milestone which strengthens our
position in Asia. The company will now have a broad patent protection in
Japan, one of the largest economies in the world" said DiaGenic CEO
Henrik Lund MD PhD.
Henrik Lund, CEO
Telephone: 47 90971219
About DiaGenic ASA
DiaGenic seeks to create value for patients, partners, and investors by
developing innovative and more patient friendly methods for early
detection of diseases utilizing DiaGenic's unique concept. The concept
implies that a disease evokes systemic responses in the blood unique for
the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression
signatures in peripheral blood and is focused on the development of
biomarkers in the field of Alzheimer's disease and Parkinson's disease.
DiaGenic's Alzheimer's disease development program includes the CE
marked diagnostic test ADtect®, for detection of mild to moderate
Alzheimer's disease, and MCItect®which is under development for
identifying patients with very early stages of Alzheimer's disease
DiaGenic's concept is protected through an extensive patent portfolio.
DiaGenic promotes its products and services towards leading
pharmaceutical, imaging and diagnostic companies. DiaGenic is located in
Norway and listed on the Oslo Stock Exchange. For more information
please visit: www.diageni